Abstract:Tumor angiogenesis is important in the growth and metastasis of malignant tumors. In our previous study, we demonstrated that an arginine-arginine-leucine (RRL) peptide is a tumor endothelial cell-specific binding sequence that may be used as a molecular probe for the imaging of malignant tumors in vivo. The aim of the present study was to further explore the characteristics of I-131-RRL by biodistribution tests, and to estimate the radiation dosimetry of I-131-RRL for humans using mice data. The RRL peptide was radiolabeled with I-131 by a chloramine-T (CH-T) method. The radiolabeling efficiency and radiochemical purity were then characterized in vitro. I-131-RRL was injected intravenously into B16 xenograft-bearing Kunming mice. Biodistribution analysis and in vivo imaging were performed periodically. The radiation dosimetry in humans was calculated according to the organ distribution and the standard medical internal radiation dose (MIRD) method in mice. All data were analyzed by statistical and MIRDOSE 3.1 software. The labeling efficiency of I-131-RRL reached 70.0 +/- 2.91% (n=5), and the radiochemical purity exceeded 95% following purification. In mice bearing B16 xenografts, I-131-RRL rapidly cleared from the blood and predominantly accumulated in the kidneys, the stomach and the tumor tissue. The specific uptake of I-131-RRL in the tumor increased over time and was significantly higher than that of the other organs, 24-72 h following injection (P<0.05). The ratio of tumor-to-skeletal muscle (T/SM) tissue exceeded 4.75, and the ratio of the tumor-to-blood (T/B) tissue peaked at 3.36. In the single-photon emission computed tomography (SPECT) imaging of Kunming mice bearing B16 xenografts, the tumors were clearly identifiable at 6 h, and significant uptake was evident 24-72 h following administration of I-131-RRL. The effective dose for the adult male dosimetric model was estimated to be 0.0293 mSv/MBq. Higher absorbed doses were estimated for the stomach (0.102 mGy/MBq), the small intestines (0.0699 mGy/MBq), the kidneys (0.0611 mGy/MBq) and the liver (0.055 mGy/MBq). These results highlight the potential of I-131-RRL as a ligand for the SPECT imaging of tumors. Administration of I-131-RRL led to a reasonable radiation dose burden and was safe for human use.

Use of Radioiodinated Peptide Arg-Arg-Leu Targeted to Neovasculari- Zation As Well As Tumor Cells in Molecular Tumor Imaging.

The Further Study on Radioiodinated Peptide Arg-Arg-Leu Targeted to Neovascularization As Well As Tumor Cells in Molecular Tumor Imaging

Technetium-99m- Arg-Arg-Leu(g2), a Modified Peptide Probe Targeted to Neovascularization in Molecular Tumor Imaging.

A novel radioiodinated peptide of arginine-arginine-leucine(RRL)for biodistribution and tumor angiogenic endothelium imaging

Study of Novel Peptide Probe 131 I-RRL for Tumor Molecular Imaging

A Novel Tc-99m-Labeled Molecular Probe For Tumor Angiogenesis Imaging In Hepatoma Xenografts Model: A Pilot Study

Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors

Molecular Imaging of Tumor Angiogenesis Using Rgd-Labeled Iron Oxide Nanoparticles

131)I Labeling and Bioactivity Evaluation of a Novel RGD Dimer Targeted to Integrin Αvβ3 Receptor

Arginine-Arginine-Leucine Peptide Targeting Heat Shock Protein 70 for Cancer Imaging

Studies on distribution and imaging of 131I-labelled RGD peptide in mice bearing tumors

Radiolabeled Cyclic RGD Peptides As Radiotracers for Tumor Imaging.

One-step Radiosynthesis of 18F-Alf-nota-rgd2 for Tumor Angiogenesis PET Imaging

A Novel 99mTc-Labeled Molecular Probe for Tumor Angiogenesis Imaging in Hepatoma Xenografts Model:A Preliminary Study

Detection of Pulmonary Metastases with the Novel Radiolabeled Molecular Probe, (99M)tc-Rrl.

Molecular Imaging and Preclinical Studies of Radiolabeled Long-Term RGD Peptides in U-87 MG Tumor-Bearing Mice

Noninvasive PET Imaging of a Ga-68-Radiolabeled RRL-Derived Peptide in Hepatocarcinoma Murine Models

Validation study of 131I-RRL: Assessment of biodistribution, SPECT imaging and radiation dosimetry in mice

Design, Synthesis and Iodination of an Arg‐Arg‐Leu Peptide for Potential Use As an Imaging Agent for Human Prostate Carcinoma

18F Labeled RGD‐A7R Peptide for Dual Integrin and VEGF‐targeted Tumor Imaging in Mice Bearing U87MG Tumors

Progress and prospect of molecular probes of radionuclide tracing targeted tumor angiogenesis